CORRECTED-ClearPoint Neuro Q4 revenue rises on IRRAS acquisition

Overview

• US device and gene therapy-enabling firm's Q4 revenue grew 34% yr/yr, driven by IRRAS acquisition

• Company completed IRRAS Holdings acquisition, expanding into neurocritical care product lines

• Q4 gross margin stable at 62%, operating expenses rose due to acquisition and expansion

Outlook

• ClearPoint Neuro expects 2026 revenue between $52 mln and $56 mln

• Company expects all four product lines to grow double digits in 2026

• Company anticipates additional revenue from biopharma partners as regulatory approvals progress

Result Drivers

• IRRAS ACQUISITION - Q4 revenue growth driven by addition of IRRAflow product line following IRRAS Holdings acquisition

• TRIAL DEMAND - Higher biologics and drug delivery revenue attributed to greater demand for disposables as partners advanced clinical trials

• NEW PRODUCT OFFERINGS - Full-year growth in neurosurgery navigation and therapy revenue supported by new offerings, including SmartFrame OR, Prism Laser Therapy, and updated operating room software

Company press release: ID:nACS02mRha

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Clearpoint Neuro Inc is $18.00, about 63.2% above its March 16 closing price of $11.03

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.